Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Medication Treatments

News
Study Finds No Significant Link Between Cannabis Use and Relapse in OUD Patients
01/26/2024

Tom Valentino

Tom Valentino
A recent meta-analysis of 10 longitudinal studies conducted by Yale University researchers found no significant link between cannabis use and relapse on non-medical opioids among patients receiving medication-assisted treatment for opioid use...
A recent meta-analysis of 10 longitudinal studies conducted by Yale University researchers found no significant link between cannabis use and relapse on non-medical opioids among patients receiving medication-assisted treatment for opioid use...
A recent meta-analysis of 10...
01/26/2024
Addiction Professional
News
Costs, Scarcity Remain Problematic for Families Seeking Adolescent Residential Addiction Treatment
01/09/2024
Tom Valentino, Digital Managing Editor
New research from Oregon Health & Science University highlights challenges related to finding residential addiction treatment for adolescents, with medication-assisted treatment options especially scarce.
New research from Oregon Health & Science University highlights challenges related to finding residential addiction treatment for adolescents, with medication-assisted treatment options especially scarce.
New research from Oregon Health...
01/09/2024
Addiction Professional
News
Telehealth-Based Initiation Associated With Improved OUD Treatment Retention
10/18/2023
Tom Valentino, Digital Managing Editor
OUD patients who initiated buprenorphine treatment through telehealth have been found more likely to remain engaged with treatment longer than those who began treatment in a non-telehealth setting, according to a new NIDA study.
OUD patients who initiated buprenorphine treatment through telehealth have been found more likely to remain engaged with treatment longer than those who began treatment in a non-telehealth setting, according to a new NIDA study.
OUD patients who initiated...
10/18/2023
Addiction Professional
Kelly Olson, PhD
News
Recovery for Patients Prescribed Medications for OUD Jeopardized by Concurrent Polysubstance Use
10/06/2023
Tom Valentino, Digital Managing Editor
Practitioners must be aware of concurrent use of non-prescribed, illicit substances that can negatively impact treatment and potentially harm patients being treated with medications for opioid use disorder, says Millennium Health Director of...
Practitioners must be aware of concurrent use of non-prescribed, illicit substances that can negatively impact treatment and potentially harm patients being treated with medications for opioid use disorder, says Millennium Health Director of...
Practitioners must be aware of...
10/06/2023
Addiction Professional
News
Report Shows Discrepancies in MOUD Utilization Among Medicaid Enrollees
10/03/2023
Tom Valentino, Digital Managing Editor
About one-third of Medicaid enrollees with opioid use disorder in 2021 did not receive treatment, and certain demographic groups were disproportionately impacted, according to a recent HHS report.
About one-third of Medicaid enrollees with opioid use disorder in 2021 did not receive treatment, and certain demographic groups were disproportionately impacted, according to a recent HHS report.
About one-third of Medicaid...
10/03/2023
Addiction Professional
take the quiz
Quiz
What is the prevalence of stimulant misuse among patients with ADHD who receive non-stimulant treatment?
09/21/2023
Of the 3.3% of youth in a recent study that had exclusively undergone non-stimulant therapy for ADHD, what percentage reported prescription stimulant misuse in the past year?
Of the 3.3% of youth in a recent study that had exclusively undergone non-stimulant therapy for ADHD, what percentage reported prescription stimulant misuse in the past year?
Of the 3.3% of youth in a recent...
09/21/2023
Psych Congress Network
News
Just 22% of US Adults With OUD Receive Medication-Assisted Treatment
08/07/2023
Tom Valentino, Digital Managing Editor
A study released by NIDA, NIH, and CDC finds that 22% of US adults with opioid use disorder receive MAT, and certain demographic groups are disproportionately impacted.
A study released by NIDA, NIH, and CDC finds that 22% of US adults with opioid use disorder receive MAT, and certain demographic groups are disproportionately impacted.
A study released by NIDA, NIH,...
08/07/2023
Addiction Professional
News
Study Highlights Challenges for Buprenorphine Prescribers
08/01/2023
Tom Valentino, Digital Managing Editor
Clinicians waivered under education-exempted HHS buprenorphine practice guidelines were less likely than traditionally waivered clinicians to prescribe buprenorphine and more likely to practice in emergency/urgent care settings, according to...
Clinicians waivered under education-exempted HHS buprenorphine practice guidelines were less likely than traditionally waivered clinicians to prescribe buprenorphine and more likely to practice in emergency/urgent care settings, according to...
Clinicians waivered under...
08/01/2023
Addiction Professional
News
Insurance Coverage of Buprenorphine Varies Widely By Formulation
07/18/2023
Tom Valentino, Digital Managing Editor
A new study released by the University of Central Florida finds that although most insurance plans cover the sublingual formulation of buprenorphine, significant barriers exist for the extended-release, injectable formulation.
A new study released by the University of Central Florida finds that although most insurance plans cover the sublingual formulation of buprenorphine, significant barriers exist for the extended-release, injectable formulation.
A new study released by the...
07/18/2023
Addiction Professional
News
Drug Candidate Shows Promise in Treating Cannabis Use Disorder
07/05/2023
Tom Valentino, Digital Managing Editor
A drug designed to treat cannabis use disorder by selectively inhibiting the signaling pathway of the cannabinoid receptor has shown promise as a safe and effective treatment in a recent clinical trial.
A drug designed to treat cannabis use disorder by selectively inhibiting the signaling pathway of the cannabinoid receptor has shown promise as a safe and effective treatment in a recent clinical trial.
A drug designed to treat...
07/05/2023
Addiction Professional

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement